Highlights

  • Dimerix shares rose 4.00% during the morning session on 23 July 2026 after announcing a key US patent grant for DMX-652.
  • The newly granted patent provides composition of matter protection for DMX-652 in the United States until 11 April 2043.
  • The company is preparing to commence a Phase 2 clinical trial for DMX-652 in acute kidney injury associated with cardiac surgery.
  • DMX-652 was recently acquired as a Phase 2-ready asset and is supported by an existing open US Investigational New Drug application.
  • The patent term includes an additional 677 days of adjustment granted by the United States Patent and Trademark Office, extending commercial protection beyond the originally anticipated expiry.

Dimerix Ltd (ASX:DXB) traded 4.00% higher at AUD 0.26 during the morning session on 23 July 2026 after announcing a significant intellectual property milestone for its recently acquired drug candidate, DMX-652. Although the stock remains down 51.85% over the past year, investors appeared to respond positively to the company's latest update, which strengthens the long-term protection of its new clinical-stage asset as preparations continue for its next phase of development.

About Dimerix

Dimerix is a clinical-stage biopharmaceutical company focused on developing therapies for kidney diseases where treatment options remain limited. The company's lead candidate, DMX-200, is currently undergoing Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS), while it has also expanded its pipeline through the addition of DMX-652, a Phase 2-ready program targeting acute kidney injury (AKI). Dimerix is supported by a network of five commercial partners that assist with global development and future commercialisation initiatives.

US Patent Extends Protection for DMX-652

The centrepiece of Dimerix's latest announcement was the granting of a core United States patent covering DMX-652 by the United States Patent and Trademark Office (USPTO). The patent, titled "N-cyanopyrrolidines with activity as USP30 inhibitors," has been issued under patent number US 12,679,833.

The newly granted patent provides composition of matter protection for DMX-652 until 11 April 2043, including 677 days of patent term adjustment awarded by the USPTO. This extends the anticipated protection period by approximately two years beyond the original expected expiry in 2041.

Composition of matter patents are regarded as one of the key forms of intellectual property protection for pharmaceutical assets because they protect the underlying chemical compound itself. For Dimerix, the extended patent life increases the period during which the company may retain exclusive rights over DMX-652 in the United States.

The company also confirmed that it has filed a divisional patent application to pursue additional intellectual property claims covering the asset.

Recently Acquired Asset Continues to Progress

DMX-652 entered Dimerix's pipeline following its recently announced acquisition of the Phase 2-ready program. The company noted that the asset has the potential to progress into a Phase 2 clinical study under an existing open US Investigational New Drug (IND) application.

Beyond the intellectual property rights, the acquisition included several assets designed to support clinical development. These include an FDA-approved Phase 2 clinical trial protocol, sufficient Good Manufacturing Practice (GMP) pharmaceutical-grade drug product for the planned study and the associated manufacturing methodology required for future development activities.

These elements provide Dimerix with a foundation as it advances preparations for the next clinical stage of the program.

Preparations Continue for Phase 2 Acute Kidney Injury Study

Alongside the patent announcement, Dimerix confirmed that preparations are continuing for the Phase 2 clinical trial of DMX-652 in patients with acute kidney injury associated with cardiac surgery.

According to the company, the planned trial will investigate whether DMX-652 can help prevent kidney injury while preserving renal function following surgery.

The initial target indication focuses on acute kidney injury occurring after cardiac surgery, although Dimerix indicated that the program could have potential applications across additional renal and non-renal indications in the future.

Chief Executive Officer and Managing Director Dr Nina Webster said the patent grant represents an important milestone for the company as it strengthens Dimerix's intellectual property portfolio while protecting its newly acquired asset in the United States until at least 2043.

She also noted that approximately one in four patients develops acute kidney injury following on-pump cardiac surgery, while there are currently no approved therapies available for the condition. According to the company, DMX-652 has the potential to reduce intensive care duration, lower the requirement for dialysis, minimise permanent kidney damage and ultimately reduce mortality if successfully developed.

Addressing an Area of Significant Unmet Medical Need

Acute kidney injury remains a serious clinical condition that develops rapidly, often within hours, and can occur in several high-risk settings including cardiac surgery and sepsis.

Dimerix estimates that the addressable patient population across the United States, Germany, France, Italy, Spain and the United Kingdom totals approximately 260,000 patients annually. Based on this population size, the company believes the indication has the potential to qualify for orphan designation.

Currently, there are no approved therapies specifically available for acute kidney injury. Patients experiencing the condition face increased risks of chronic kidney disease and long-term kidney complications following the initial episode.

The absence of approved treatment options is one of the reasons Dimerix believes DMX-652 could address an important unmet medical need if future clinical studies demonstrate favourable outcomes.

How DMX-652 Is Designed to Work

DMX-652 is described by Dimerix as a selective inhibitor of USP30, a mitochondrial enzyme involved in regulating the removal of damaged mitochondria.

The therapy is designed to promote mitochondrial quality control within injured kidney cells by inhibiting USP30 activity. According to the company, this mechanism may assist in kidney injury caused by reduced blood flow, toxins and sepsis-related factors.

DMX-652 is being developed as a once-daily oral capsule, offering a convenient route of administration for future clinical use if successfully commercialised.

The planned Phase 2 study will evaluate whether this mechanism can help prevent kidney injury and preserve kidney function in patients undergoing cardiac surgery.

Broader Kidney Disease Pipeline Remains Active

Alongside DMX-652, Dimerix continues advancing its lead development program, DMX-200.

DMX-200 is currently in Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS), a rare kidney disease characterised by progressive scarring of the kidney's filtering units. The condition often results in declining kidney function and may progress to end-stage kidney disease.

The company estimates that more than 40,000 people in the United States are living with FSGS. At present, there are no therapies specifically approved for the disease in the United States.

DMX-200 is administered alongside the standard of care angiotensin II type I receptor blocker and is protected by granted patents in multiple territories until 2032, while additional patent applications may extend protection through 2042. The therapy has also received Orphan Drug Designation in the United States, Europe, the United Kingdom and Japan.

Intellectual Property Strengthens Long-Term Development Strategy

For biotechnology companies, intellectual property protection forms an important component of long-term development planning because it supports future commercial opportunities while safeguarding innovation.

With patent protection for DMX-652 now extending until 2043 in the United States, Dimerix has strengthened the commercial positioning of the asset as it progresses towards Phase 2 clinical development.

Combined with the existing FDA-cleared Phase 2 protocol, open IND application and supporting manufacturing package acquired with the program, the latest patent milestone represents another step in advancing DMX-652 through clinical development.

Conclusion

Dimerix's latest announcement centres on strengthening the long-term intellectual property position of DMX-652 through the grant of a key US composition of matter patent extending protection until 2043. The update comes shortly after the company acquired the Phase 2-ready asset and as preparations continue for a clinical study in acute kidney injury associated with cardiac surgery. With no approved therapies currently available for the targeted indication and development activities progressing, investors will continue monitoring future clinical milestones for both DMX-652 and the company's broader kidney disease pipeline.